Blueprint Medicines — Investor Presentation (January 2019)
31 slides from Blueprint Medicines's investor presentation, Jan 7, 2019
Slide 1: 2020 Blueprint global business strategy
2020 Blueprint global business strategy January 7, 2019
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,”
Slide 3: Precision therapies for people with cancer and rare diseases
Precision therapies for people with cancer and rare diseases Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com) (CSTI). The foregoing website is maintained by CSTI, and Blueprint Medicines is not responsible for its content. 3 A new way of looking at kina
Slide 4: The promise of precision therapy throughout the development cycle
The promise of precision therapy throughout the development cycle HCP, healthcare professional 4 Rational drug design selectively targets genetic drivers of disease Efficient clinical development with small trials and focused investment Demonstrable value to patients, HCPs, payers and healthcare sys
Slide 5: Our vision for a sustainable precision therapy company
Our vision for a sustainable precision therapy company 5 Robust scientific platform reproducibly designing potent and selective kinase medicines Disciplined portfolio management focusing on therapeutic area leadership and novel targets Effective and nimble commercial organization delivering medicine
Slide 6: Our '2020 Blueprint' strategy to make this vision a reality
Our “2020 Blueprint” strategy to make this vision a reality 6 2 marketed products in the US 4 pending marketing applications in the US and EU 6 therapeutic candidates in global clinical development 8 research programs Global commercial footprint, with 2 marketed products in the US and 1 marketed pro
Slide 7: Registration-enabling trials to build on first potential avapritinib approval
7 registration-enabling trials to build on first potential avapritinib approval 2L, second-line; 3L, third-line; 4L, fourth-line; GIST, gastrointestinal stromal tumors; MTC, medullary thyroid cancer; NSCLC, non-small cell lung cancer; SM, systemic mastocytosis. 7 Program Trial NAME Target indication
Slide 8: Research areas of focus leverage robust scientific platform
Research areas of focus leverage robust scientific platform, clinical expertise and planned commercial profile 8 Leadership in therapeutic areas of focus Cancer immunotherapy under Roche collaboration Novel genetic drivers Plan to disclose up to 2 new targets at R&D day in 2019 Systemic mastocytosis
Slide 9: Rapidly advancing pipeline of investigational precision therapies
DRUG CANDIDATE (TARGET) DISCOVERY EARLY CLINICAL DEVELOPMENT LATE CLINICAL DEVELOPMENT REGULATORY SUBMISSION APPROVED COMMERCIAL RIGHTS Avapritinib (KIT & PDGFRA) BLU-667 (RET) BLU-554 (FGFR4) BLU-782 (ALK2) 4 undisclosed targets Immunokinase targets Rapidly advancing pipeline of investigational pre
Slide 10: Avapritinib: an investigational precision therapy with broad commercial potential
Avapritinib: an investigational precision therapy with broad commercial potential *CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib in Mainland China, Hong Kong, Macau and Taiwan. **Represents estimated number of patients with PDGFRA-driven GIST; 2L, 3L, 4L KIT-dr
Slide 11: Avapritinib is a potentially transformative selective KIT/PDGFRA inhibitor
Avapritinib is a potentially transformative selective KIT/PDGFRA inhibitor Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com) (CSTI). The foregoing website is maintained by CSTI, and Blueprint Medicines is not responsible for its content. All compounds we
Slide 12: Beyond imatinib, there are no highly effective therapies for advanced GIST
Beyond imatinib, there are no highly effective therapies for advanced GIST PFS, progression free survival. * Imatinib re-challenged. 12 1L 2L 3L 4L imatinib ORR ~60% PFS 19 months sunitinib ORR ~7% PFS 6 months regorafenib ORR ~5% PFS 4.8 months No approved therapy ORR ~0% PFS 1.8 months* - All appr
Slide 13: High response and clinical benefit rates in PDGFRα D842V-mutant GIST
Maximum reduction: sum of diameter change from baseline (%) High response and clinical benefit rates in PDGFRα D842V-mutant GIST 1 Data previously presented in November 2018 at the CTOS Annual Meeting. Data cutoff: October 15, 2018. 2 Top-line data will be used to support planned NDA submission in 1
Slide 14: ~20% ORR in ≥4L KIT-driven GIST patients
~20% ORR in ≥4L KIT-driven GIST patients 1 Data previously presented in November 2018 at the CTOS Annual Meeting. Data cutoff: October 15, 2018. 2 Top-line data will be used to support planned NDA submission in 1H 2019. Data cutoff: November 16, 2018. Median PFS (central radiology) same as reported
Slide 15: Avapritinib is well-tolerated in patients with GIST
Avapritinib is well-tolerated in patients with GIST Treatment-Emergent Adverse Events (Safety Population; N = 231) Adverse event (AE), % (n) Any Grade Grade 1 Grade 2 Grade 3 Grade 4 Nausea 61% (142) 46% (106) 13% (30) 3% (6) 0 Fatigue 55% (127) 21% (48) 28% (64) 6% (15) 0 Anemia 46% (107) 5% (11) 1
Slide 16: Preliminary 26% ORR for avapritinib versus 5% ORR for regorafenib
Preliminary 26% ORR for avapritinib1 versus 5% ORR for regorafenib2 Preliminary Phase 1 data in 3L/4L regorafenib-naïve GIST de-risk ongoing Phase 3 VOYAGER trial 1 Data previously presented in November 2018 at the CTOS Annual Meeting. Data cutoff: October 15, 2018. 2 Regorafenib data in FDA-approve
Slide 17: Phase 1 data support design of COMPASS-2L trial in 2L GIST
Preliminary Phase 1 data support design of Phase 3 COMPASS-2L trial in genotype-selected 2L GIST population ctDNA, circulating tumor DNA. 1 Data previously presented in November 2018 at the CTOS Annual Meeting. Data cutoff: October 15, 2018. ctDNA analysis in ≥4L population. 17 V654A and T670I negat
Slide 18: Avapritinib is the only highly selective KIT D816V inhibitor in development for SM
SM with Associated Hematologic Neoplasm (SM-AHN) Aggressive SM (ASM) Mast Cell Leukemia (MCL) Advanced SM Spectrum Patient impact Indolent SM (ISM) Smoldering SM (SSM) ~90-95% of patients have KIT D816V mutation1 Avapritinib is the only highly selective KIT D816V inhibitor in development for systemi
Slide 19: Clinical activity in all evaluable patients with advanced SM
47% normalization 66% <20ng/mL 6% molecular clearance Best percentage change from baseline (%) *prior midostaurin # prior DCC-2618 + S/A/R mutation positive Spleen Volume (central review) Serum Tryptase (central assay) Blood KIT D816V ddPCR (central assay) Bone marrow mast cells Clinical activity in
Slide 20: Responses are durable and deepen over time
Best response* n (%) All doses (n=29) ORR (CR + CRh + PR + CI) 24 (83%) Complete response (CR) 3 (10%) CR, partial hematologic recovery2 (CRh) 4 (14%) Partial response (PR) 14 (48%) Clinical improvement (CI) 3 (10%) Stable disease (SD) 5 (17%) Progressive disease (PD) 0 ≤200mg1 QD (n=10) 9 (90%) 3 (
Slide 21: Avapritinib is well-tolerated in patients with systemic mastocytosis
Avapritinib is well-tolerated in patients with systemic mastocytosis 21 Treatment-Emergent Adverse Events (Safety Population; N = 67) Non-hematologic AEs >15%, % (n) Any Grade Grade 3/4 Periorbital edema 45 (67) 3 ( 4) Fatigue 25 (37) 5 ( 7) Nausea 24 (36) 3 ( 4) Diarrhea 23 (34) 1 ( 1) Peripheral E
Slide 22: Preliminary Phase 1 data highlight the potential of avapritinib in ISM/SSM
Evaluable ISM/SSM patients in Phase 1 EXPLORER trial Preliminary Phase 1 data highlight the potential of avapritinib in ISM/SSM Data previously presented in December 2018 at the ASH Annual Meeting. Data cutoff: September 30, 2018. BM, bone marrow; ISM, indolent systemic mastocytosis; RP2D, recommend
Slide 23: Growing portfolio of highly selective investigational kinase medicines
Growing portfolio of highly selective investigational kinase medicines 23 Non-small cell lung cancer Medullary thyroid cancer Other RET-altered solid tumors BLU-667 RET inhibitor Hepatocellular carcinoma BLU-554 FGFR4 inhibitor Fibrodysplasia ossificans progressiva BLU-782 ALK2 inhibitor Kinome illu
Slide 24: Plan to submit NDA for 2L RET-fusion NSCLC and 2L RET-mutant MTC in 1H 2020
Plan to submit NDA for 2L RET-fusion NSCLC and 2L RET-mutant MTC in 1H 2020 25 Dose escalation RET-altered solid tumors RET-fusion NSCLC, prior platinum Part 1 complete MTC, prior MKI Part 2 enrolling RET-fusion solid tumors, prior standard of care RET-mutated tumors, prior standard of care RET-alte
Slide 25: Data have strengthened as patients treated at RP2D
Data have strengthened as patients treated at RP2D 26 AACR April 20181 ATA October 20182 84% of patients with tumor shrinkage (NSCLC, MTC and PTC) 53% ORR in RET-fusion NSCLC and PTC patients 40% ORR in RET-mutant MTC patients 90% of patients with tumor shrinkage (MTC and PTC) 62% response rate in R
Slide 26: BLU-782 is designed to target mutant ALK2, the cause of FOP
BLU-782 is designed to target mutant ALK2, the underlying cause of fibrodysplasia ossificans progressiva 27 MALFORMED BIG TOES TUMOR-LIKE SWELLINGS EXTRASKELETAL BONE PROGRESSIVE INCAPACITATION Causes abnormal transformation of skeletal muscle, ligaments and tendons into bone Beginning in childhood,
Slide 27: Foundational preclinical data support clinical development of BLU-782 in FOP
Highly selective for mutant ALK2 Prevents surgery-induced HO* Prevents injury-induced HO* Foundational preclinical data support plans for clinical development of BLU-782 in FOP Cellular assay Micro CT at Day 17 28 Data previously presented at ASBMR Annual Meeting in September 2018. * Injury- and sur
Slide 28: Strategic collaboration with CStone in Greater China
Leader in targeted kinase medicines Three clinical programs with demonstrated proof-of-concept Retain all rights in the rest of the world Deep development experience and network in China Growing oncology portfolio including immunotherapies Exclusive rights in Greater China1 1 Greater China consists
Slide 29: Strong financial position entering 2019
Strong financial position entering 2019 30 Balance Sheet (unaudited) 9/30/2018 12/31/2017 Cash, Cash Equivalents and Investments $559.6M $673.4M Three Months Ended Statement of Operations (unaudited) 9/30/2018 9/30/2017 Collaboration Revenue $1.1M $8.1M Research & Development Expenses $64.6M $39.3M
Slide 30: Anticipated milestones by program
Program Milestone Anticipated Timing Avapritinib – GIST Submit NDA for PDGFRA Exon 18 mutant GIST and 4L GIST 1H 2019 Present data from Phase 1 NAVIGATOR trial supporting planned NDA for PDGFRA Exon 18 mutant GIST and 4L GIST 1H 2019 Complete enrollment of Phase 3 VOYAGER trial in 3L GIST 2H 2019 In
Slide 31: Thank you
(Sblveprint. Thank you
Blueprint Medicines — Investor Presentation (January 2019) on 6ix